Swedish Orphan Biovitrum
| Company type | Public |
|---|---|
| Nasdaq Stockholm: SOBI | |
| Industry | Pharmaceutical |
| Headquarters | Stockholm, Sweden |
Key people | |
| Products | Treatments in the areas of haematology, immunology and specialty care |
| Revenue | SEK 18.8 bn (2022) |
| SEK 14.4 bn (2022) | |
| Total assets | SEK 52.5 bn (2022) |
| Total equity | SEK 26.5 bn (2022) |
Number of employees | 1,600 (2022) |
| Parent | Investor AB (34.7%) |
| Website | sobi.com |
| Footnotes / references | |
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees.